



Government of Canada  
Gouvernement du Canada

266 AA

MEMORANDUM NOTE DE SERVICE

002536

TO  
A

Dr. C.T. Miller,  
Co-ordinator,  
Task Force for Re-assessment  
of Chemical Safety

SECURITY CLASSIFICATION - DE SECURITE

OUR FILE - N° REFERENCE

FROM  
DE

Dr. D.B. Davies,  
Task Force for Re-assessment  
of Chemical Safety

YOUR FILE - N° REFERENCE

DATE

November 19, 1980

SUBJECT  
OBJET

Revised: June 16, 1981

AUDIT AND VALIDATION OF THE IBT STUDY: "42-DAY NEUROTOXICITY STUDY WITH CGA-15324 TECHNICAL IN ADULT CHICKENS"

<u>NAME OF LABORATORY:</u>	INDUSTRIAL BIOTEST LABORATORIES
<u>LABORATORY REPORT NO:</u>	IBT NO. 8580-11187
<u>REPORT DATE:</u>	JULY 25, 1978
<u>COMMON NAME OF COMPOUND:</u>	PROFENOFOS
<u>OTHER NAME(S)</u>	CURACRON, SELECRON COMPANY CODE: CGA-15324
<u>FORM OF TEST MATERIAL:</u>	TECHNICAL GRADE
<u>PETITIONER:</u>	CIBA-GEIGY CORP.
<u>TYPE OF STUDY:</u>	NEUROTOXICITY
<u>SPECIES, BREED AND STRAIN:</u>	HENS
<u>FILE UNDER:</u>	PROFENOFOS
<u>RECOMMENDATION:</u>	INVALID

**BEST AVAILABLE COPY**

OVERALL COMMENTS

Although the raw data from the present study generally support the findings given in the final report, the study is adjudged invalid owing to deficiencies in experimental design and conduct, which are highlighted below:

- 1) The dosing regimen employed in the neurotoxicity study was poorly contrived and lacks scientific merit. For treatment at Day 21, doses were adjusted downward to 17.1 mg/kg from those administered on Day 0, namely 30 mg/kg and 45.7 mg/kg. Justification for this reduction was based upon the high incidence of mortality witnessed among test birds dosed at the higher levels. The higher doses were selected on the basis of mortality data generated in preliminary studies, from which an LD<sub>50</sub> of 45.7 mg/kg was estimated. There is no evidence that the dose level of 17.1 mg/kg approached the LD<sub>50</sub> value. No mortalities were observed among birds administered the lower dose. The possibility exists, therefore, that animals were not adequately challenged upon second treatment.

5